• Explore /
  • Poster
  • / Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

Abstract Poster

Authors

null

Arjun Lakshman

Division of Hematology, Mayo Clinic, Rochester, MN

Arjun Lakshman , Jithma P. Abeykoon , Shaji Kumar , S.Vincent Rajkumar , Taxiarchis Kourelis , Francis Buadi , David Dingli , Martha Lacy , Wilson I. Gonsalves , Angela Dispenzieri , Robert A. Kyle , Yi Lin , Ronald S. Go , Rahma M. Warsame , Suzanne R. Hayman , Stephen Russell , Nelson Leung , Morie A. Gertz , Prashant Kapoor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 35, 2017 (suppl; abstr 8038)

DOI

10.1200/JCO.2017.35.15_suppl.8038

Abstract #

8038

Poster Bd #

364

Abstract Disclosures

Similar Posters

First Author: Adriana C. Rossi

First Author: Katja Weisel

First Author: Dan T. Vogl

First Author: Cyrille Touzeau